Nature communications

Human stem cell models show SETBP1 may cause DNA structure changes in GATA2 deficiency

Updated

Abstract

is linked to the development of myelodysplastic neoplasms (MDS), which can progress to acute myeloid leukemia.

  • Mutations in SETBP1 and ASXL1 genes are frequently found in patients with GATA2 deficiency.
  • The impact of GATA2 mutation on hematopoietic progenitors is limited.
  • Co-occurring SETBP1 or ASXL1 mutations hinder myeloid differentiation.
  • The presence of all three mutations significantly reduces myeloid progenitor levels, mimicking GATA2-related MDS.
  • SETBP1 mutation is crucial for maintaining a stable chromatin accessibility landscape, even in the presence of ASXL1 mutation.

Simplified

Key numbers

80%
80% lifetime penetrance
Individuals with GATA2 mutations developing MDS by age 20.
7%
7% of pediatric MDS cases
Proportion of pediatric MDS cases attributed to .

Key figures

Fig. 1
Mutant and parental : hematopoietic cell differentiation and progenitor quantification
Highlights reduced myeloid progenitors and colony formation in triple-mutant cells compared to parental controls.
41467_2025_65806_Fig1_HTML
  • Panel B
    plots showing early (CD34+CD43+), late (CD34+CD45+), myeloid progenitors (CD33+CD11b+), and monocytes (CD14+) at day 15 across P, S, A, G, GS, GA, and GSA conditions; S condition appears to have higher early progenitors than P, while GSA shows visibly lower values.
  • Panel C
    Quantification of early (CD34+CD43+) at day 15 in all conditions.
  • Panel D
    Quantification of late hematopoietic progenitors (CD34+CD45+) at day 15 in all conditions.
  • Panel E
    Quantification of mature hematopoietic progenitors (CD45+) at day 15 in all conditions.
  • Panel F
    Quantification of myeloid progenitors (CD33+CD11b+) at day 15 in all conditions.
  • Panel G
    Quantification of monocytes (CD14+ within CD33+ cells) at day 15 in all conditions.
  • Panel H
    Quantification of neutrophils (CD15+ within CD33+ cells) at day 15 in all conditions.
  • Panel I
    (CFU) assay quantifying CFU-granulocyte (CFU-G), CFU-macrophage (CFU-M), CFU-granulocyte-macrophage (CFU-GM), and total colonies from day 15 EB-derived hematopoietic progenitors.
  • Panel J
    Cell-cycle analysis of CD33+ cells at day 15 using and DAPI staining across all conditions.
Fig. 2
changes in GATA2 deficient cells with SETBP1 and ASXL1 mutations
Highlights stable chromatin remodeling and distinct gene accessibility patterns linked to SETBP1 mutation in GATA2 deficient cells.
41467_2025_65806_Fig2_HTML
  • Panel A
    (PCA) shows clustering of chromatin accessibility profiles for parental (P), SETBP1 (S), ASXL1 (A), GATA2 (G), and combined mutants (GA, GS, GSA).
  • Panel B
    Tornado plots display (DAPs) across conditions with five clusters (C1-C5); signal intensity appears visibly stronger in GSA compared to P.
  • Panel C
    Venn diagrams illustrate overlap of open and closed chromatin DAPs among GA vs P, GS vs P, and GSA vs P comparisons, showing shared and unique accessibility changes.
  • Panel D
    (GSEA) lollipop plots highlight downregulation of inflammatory response and hematopoietic differentiation pathways in GS and GSA, and upregulation of gene signatures in GSA.
  • Panel E
    Volcano plots show differential chromatin accessibility peaks with labeled genes for GA vs P, GS vs P, and GSA vs P; significant peaks are colored and genes associated with these peaks are indicated.
Fig. 3
differences in iPSC-derived HSPCs across GATA2 mutation conditions
Highlights distinct chromatin accessibility and motif enrichment patterns linked to GATA2 mutation combinations in progenitor cells.
41467_2025_65806_Fig3_HTML
  • Panels A and B
    Venn diagrams show numbers of open (A) and closed (B) () comparing GA, GS, GSA versus P; tracks display chromatin accessibility at specific gene loci with color-coded conditions; open chromatin tracks (A) highlight strong and distal and promoters, with visible differences in peak intensity across conditions; closed chromatin tracks (B) similarly show regulatory elements with visibly reduced accessibility in mutant conditions compared to P.
  • Panel C
    bar graphs present top enriched transcription factor binding motifs in open (top) and closed (bottom) DAPs for GA, GS, and GSA versus P; open chromatin motifs include ETS and homeobox families with higher enrichment values, while closed chromatin motifs predominantly show GATA family motifs with strong enrichment.
  • Panel D
    Venn diagrams illustrate overlap of GATA2-target genes identified by ChIP-seq with open and closed DAPs in GA, GS, and GSA intersections; open chromatin shows 18 overlapping out of 687 genes, closed chromatin shows 229 overlapping GATA2 targets out of 714 genes.
Fig. 4
Transcriptomic changes across seven genetic mutation conditions in .
Highlights distinct gene expression and pathway changes, including reduced inflammation and increased leukemic signatures in GSA condition.
41467_2025_65806_Fig4_HTML
  • Panel A
    (PCA) of data showing clustering of seven conditions (P, S, A, G, GA, GS, GSA) based on global gene expression profiles.
  • Panel B
    Venn diagrams illustrating overlap of upregulated and downregulated (DEGs) among GA vs P, GS vs P, and GSA vs P comparisons.
  • Panel C
    Volcano plots displaying differential gene expression for GA vs P, GS vs P, and GSA vs P; significantly upregulated genes are colored red and downregulated genes blue.
  • Panel D
    (GSEA) lollipop plots showing significant downregulation of inflammatory response and hematopoietic differentiation pathways in GS and GSA, and upregulation of gene signatures in GSA.
  • Panel E
    with hierarchical clustering of gene expression profiles integrating experimental samples and reference iPSC RNA-seq data from MDS patients and healthy donor, showing transcriptomic relationships.
1 / 4

Full Text

What this is

  • This research investigates the role of SETBP1 and ASXL1 mutations in , a condition linked to myelodysplastic syndromes (MDS).
  • Using human induced pluripotent stem cells () and CRISPR/Cas9 technology, the study models the impact of these mutations on hematopoietic differentiation.
  • Findings reveal that while GATA2 mutations alone have limited effects, the combination of GATA2, SETBP1, and ASXL1 mutations leads to significant myeloid progenitor depletion.

Essence

  • SETBP1 mutations drive significant chromatin remodeling and impair myeloid differentiation in . The combination of GATA2, SETBP1, and ASXL1 mutations exacerbates these effects, leading to a severe depletion of myeloid progenitors.

Key takeaways

  • SETBP1 mutation alone promotes early hematopoietic stem/progenitor cell (HSPC) expansion but impairs differentiation when combined with GATA2 mutations. ASXL1 mutations do not independently affect differentiation but exacerbate the impairment in the presence of .
  • The combination of GATA2, SETBP1, and ASXL1 mutations results in a severe depletion of myeloid progenitors, closely mimicking the hematopoietic phenotype seen in GATA2-related MDS patients.
  • SETBP1 mutations lead to stable chromatin accessibility changes, which are crucial for understanding the epigenetic basis of myeloid malignancies in .

Caveats

  • The study's model does not replicate all cytogenetic alterations seen in , such as monosomy 7, which may limit the understanding of leukemic transformation.
  • Findings are based on in vitro models, which may not fully capture the complexities of human disease progression in .

Definitions

  • GATA2 deficiency: A genetic condition leading to hematologic disorders, including myelodysplastic syndromes and immunodeficiency.
  • hiPSCs: Human induced pluripotent stem cells, which are reprogrammed cells capable of differentiating into various cell types.

Simplified

Funding

Competing interests

Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free